

# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2020- 21/008

June 29, 2020

To,

Listing Department  
BSE Ltd  
1<sup>st</sup> Floor, New Trade Wing,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.  
Scrip Code: 532637

Listing Department  
National Stock Exchange of India Limited  
"Exchange Plaza", 5<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai - 400 051  
Symbol: MANGALAM

**Sub: Outcome of the Board Meeting held on Monday, June 29, 2020**

Dear Sir / Madam,

In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we have to inform you that the Board of Directors of the Company, in their meeting held today i.e. Monday, June 29, 2020 has *inter-alia* approved the Audited Financial Results (Standalone) for the quarter and year ended March 31, 2020 pursuant to Regulation 33 of the Listing Regulations. A copy of the said results, notes thereto and Auditor's Report is enclosed for your records.

We hereby declare that the Auditors have expressed an unmodified opinion in the Audit Report on the Standalone Audited Financial Results for the quarter and year ended March 31, 2020.

The meeting of Board of Directors of the Company commenced at 3:00 P.M. and concluded at 4:50 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,  
For Mangalam Drugs & Organics Limited



Geeta Karira  
Company Secretary & Compliance officer

**Audited Financial Results for the Year Ended 31st March 2020 approved and taken on record by the Board at their meeting dated  
29th June, 2020**

Sr.No	Particulars	Quarter Ended			(Rs. In Lacs)	
					Year Ended	
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Unaudited	Audited	Audited	Audited
<b>A) Part-1 Statement of Audited Financial Results for the Year Ended March 31, 2020</b>						
1	Revenue from Operations	8,809.46	6,194.36	4,808.91	28,235.36	22,757.97
2	Other Income	45.33	65.90	20.53	118.12	31.68
3	Total Revenue(1+2)	8,854.79	6,260.26	4,829.44	28,353.48	22,789.65
4	Expenses					
	(a) Cost of Materials Consumed	5,279.54	3,744.41	3,737.07	17,807.14	16,870.28
	(b) Purchase of Stock in trade					0.00
	(c) Changes in Inventories of, Finished Goods and Stock-in-trade & Work In Progress	1,084.22	408.34	(181.73)	1,727.66	(1,538.93)
	(d) Employee Benefits Expenses	705.66	635.28	648.00	2,604.41	2,581.65
	(e) Finance Costs	246.29	254.45	252.54	1,040.47	864.65
	(f) Depreciation & amortization expenses	209.61	205.75	165.70	821.78	708.85
	(g) Other Expenses	1,024.11	910.46	579.19	3,726.81	3,876.85
	Total Expenses	8,549.43	6,158.69	5,200.78	27,728.27	23,363.35
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	305.36	101.57	(371.34)	625.21	(573.71)
6	Exceptional items	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	305.36	101.57	(371.34)	625.21	(573.71)
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	305.36	101.57	(371.34)	625.21	(573.71)
10	Tax Expenses					
	Current Tax	34.69	11.85	-00	110.10	0.00
	Less: MAT credit entitlement / reversal	(29.33)	(75.41)	-00	(104.74)	
	Deferred Tax	(205.40)	0.00	229.38	(205.40)	229.38
11	Net Profit(+)/Loss(-) after Tax (9-10)	505.40	165.13	(600.72)	825.25	(803.09)
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	0.32	0.87	0.43	2.32	1.69
13	Total Comprehensive Income	505.72	166.00	(600.29)	827.57	(801.40)
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity				8,811.05	7,983.48
16	Earnings Per Share (EPS) (of Rs 10/-each not annualised):					
	(a) Basic	3.19	1.04	(3.80)	5.21	(5.07)
	(b) Diluted	3.19	1.04	(3.80)	5.21	(5.07)

**Notes :**

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on June 29, 2020. The Statutory Auditors have expressed an unmodified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- The Company has implemented Ind AS 116 with retrospective effect. The impact of depreciation and unwinding of interest cost along with lease liability and right of use (Asset) on opening balance of other equity is 9.32 Lakhs. Company has created lease liability amounting to Rs 232.20 Lakhs and Right of Use Assets amounting to Rs 222.88 Lakhs.
- The figures for the quarter ended March 31, 2020 and March 31, 2019 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.
- The World Health Organization announced a global health emergency because of a new strain of coronavirus ("COVID-19") and classified its outbreak as a pandemic on March 11, 2020. The Indian government announced a strict lockdown across the country to contain the spread of the virus, which was extended till May 31, 2020. The Company is engaged in manufacturing of essential commodities and consequently the impact of the pandemic is not significant. As of today, production facilities remained operational, following enhanced internal safety guidelines and directives issued by the Ministry of Home Affairs and State Government. The company has assessed the impact of this whole situation and is of the view that based on its present assessment this situation does not materially impact the Standalone financial results as on March 31, 2020. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- Deferred Tax calculation as per Ind AS 12 is considered by the Company on annual basis.
- Earlier period figures have been regrouped/ rearranged wherever necessary.

Place: Mumbai  
Date: 29th June, 2020



On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)  
Chairman & Managing Director  
(DIN:01240086)

